Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADIPOR2 | Q86V24 | 1/20 | 0.67 |
| ▸ | ADIPOR1 | Q96A54 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.64 |
| ▸ | USP2 | O75604 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | MCHR1 | Q99705 | 6/20 | 0.59 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.58 |
| ▸ | HRH1 | P35367 | 1/20 | 0.56 |
| ▸ | CCR3 | P51677 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4170568 | 0.92 | ADIPOR2 (0.58) | ADIPOR2ADIPOR1POLBSIGMAR1USP2 | |
| SCHEMBL24514572 | 0.91 | ADIPOR2 (0.81) | ADIPOR2ADIPOR1POLBSIGMAR1USP2 | |
| SCHEMBL2210339 | 0.91 | ADIPOR2 (0.63) | ADIPOR2ADIPOR1POLBSIGMAR1USP2 | |
| SCHEMBL17950923 | 0.91 | ADIPOR2 (0.63) | ADIPOR2ADIPOR1POLBSIGMAR1USP2 | |
| SCHEMBL4036078 | 0.91 | POLB (0.65) | ADIPOR2ADIPOR1POLBSIGMAR1USP2 | |
| SCHEMBL24514569 | 0.90 | ADIPOR2 (0.70) | ADIPOR2ADIPOR1POLBSIGMAR1USP2 | |
| SCHEMBL4161579 | 0.90 | SIGMAR1 (0.70) | ADIPOR2ADIPOR1POLBSIGMAR1USP2 | |
| SCHEMBL17950944 | 0.89 | USP2 (0.77) | ADIPOR2ADIPOR1POLBSIGMAR1USP2 | |
| SCHEMBL4031641 | 0.89 | POLB (0.70) | ADIPOR2ADIPOR1POLBSIGMAR1USP2 | |
| SCHEMBL17951031 | 0.89 | MCHR1 (0.68) | ADIPOR2ADIPOR1POLBSIGMAR1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090197914-A1 | Piperidine Derivatives, Their Process for Preparation, Their Use as Therapeutic Agents and Pharmaceutical Compositions Containing Them | ASTRAZENECA AB (SE) | 2009-08-06 | — | — | US | disclosed |
| EP-1994003-A1 | PIPERIDINE DERIVATIVES, THEIR PROCESS FOR PREPARATION, THEIR USE AS THERAPEUTIC AGENTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM . | AstraZeneca AB (SE) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007102768-A1 | PIPERIDINE DERIVATIVES, THEIR PROCESS FOR PREPARATION, THEIR USE AS THERAPEUTIC AGENTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM . | ASTRAZENECA AB (SE) | 2007-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197914-A1 | Piperidine Derivatives, Their Process for Preparation, Their Use as Therapeutic Agents and Pharmaceutical Compositions Containing Them | CCR3, CCR1, CCR4 | ADIPOR2 1677/4885ADIPOR1 938/4885POLB 1372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.